0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Resectable non-stage IV nonsmall cell lung cancer: the surgical perspective

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Surgery remains an essential element of the multimodality radical treatment of patients with early-stage nonsmall cell lung cancer. In addition, thoracic surgery is one of the key specialties involved in the lung cancer tumour board. The importance of the surgeon in the setting of a multidisciplinary panel is ever-increasing in light of the crucial concept of resectability, which is at the base of patient selection for neoadjuvant/adjuvant treatments within trials and in real-world practice. This review covers some of the topics which are relevant in the daily practice of a thoracic oncological surgeon and should also be known by the nonsurgical members of the tumour board. It covers the following topics: the pre-operative selection of the surgical candidate in terms of fitness in light of the ever-improving nonsurgical treatment alternatives unfit patients may benefit from; the definition of resectability, which is so important to include patients into trials and to select the most appropriate radical treatment; the impact of surgical access and surgical extension with the evolving role of minimally invasive surgery, sublobar resections and parenchymal-sparing sleeve resections to avoid pneumonectomy.

          Tweetable abstract

          Surgery represents a key element in the multidisciplinary management of lung cancer. Surgical aspects such as operability, resectability, surgical access and extent of resection are important and should be learned by all nonsurgical members of the MDT. https://bit.ly/41WDYmx

          Related collections

          Most cited references156

          • Record: found
          • Abstract: not found
          • Article: not found

          Frailty in Older Adults: Evidence for a Phenotype

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Reduced lung-cancer mortality with low-dose computed tomographic screening.

            (2011)
            The aggressive and heterogeneous nature of lung cancer has thwarted efforts to reduce mortality from this cancer through the use of screening. The advent of low-dose helical computed tomography (CT) altered the landscape of lung-cancer screening, with studies indicating that low-dose CT detects many tumors at early stages. The National Lung Screening Trial (NLST) was conducted to determine whether screening with low-dose CT could reduce mortality from lung cancer. From August 2002 through April 2004, we enrolled 53,454 persons at high risk for lung cancer at 33 U.S. medical centers. Participants were randomly assigned to undergo three annual screenings with either low-dose CT (26,722 participants) or single-view posteroanterior chest radiography (26,732). Data were collected on cases of lung cancer and deaths from lung cancer that occurred through December 31, 2009. The rate of adherence to screening was more than 90%. The rate of positive screening tests was 24.2% with low-dose CT and 6.9% with radiography over all three rounds. A total of 96.4% of the positive screening results in the low-dose CT group and 94.5% in the radiography group were false positive results. The incidence of lung cancer was 645 cases per 100,000 person-years (1060 cancers) in the low-dose CT group, as compared with 572 cases per 100,000 person-years (941 cancers) in the radiography group (rate ratio, 1.13; 95% confidence interval [CI], 1.03 to 1.23). There were 247 deaths from lung cancer per 100,000 person-years in the low-dose CT group and 309 deaths per 100,000 person-years in the radiography group, representing a relative reduction in mortality from lung cancer with low-dose CT screening of 20.0% (95% CI, 6.8 to 26.7; P=0.004). The rate of death from any cause was reduced in the low-dose CT group, as compared with the radiography group, by 6.7% (95% CI, 1.2 to 13.6; P=0.02). Screening with the use of low-dose CT reduces mortality from lung cancer. (Funded by the National Cancer Institute; National Lung Screening Trial ClinicalTrials.gov number, NCT00047385.).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

              The IASLC Staging and Prognostic Factors Committee has collected a new database of 94,708 cases donated from 35 sources in 16 countries around the globe. This has now been analysed by our statistical partners at Cancer Research And Biostatistics and, in close collaboration with the members of the committee proposals have been developed for the T, N, and M categories of the 8th edition of the TNM Classification for lung cancer due to be published late 2016. In this publication we describe the methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition.
                Bookmark

                Author and article information

                Journal
                Eur Respir Rev
                Eur Respir Rev
                ERR
                errev
                European Respiratory Review
                European Respiratory Society
                0905-9180
                1600-0617
                31 January 2024
                20 March 2024
                : 33
                : 171
                : 230195
                Affiliations
                [1 ]Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
                [2 ]Department of Thoracic Surgery, Marmara University, Istanbul, Turkey
                [3 ]Division of Respiratory Medicine and Thoracic Oncology, and Thoracic Oncology Centre Munich, Ludwig-Maximilians-Universität in Munich, Munich, Germany
                [4 ]Department of Thoracic Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
                [5 ]Department of Cardio-Thoracic Surgery, CUHK Medical Centre, Hong Kong, China
                [6 ]Department of Thoracic Surgery, Ljubljana University Medical Centre, Ljubljana, Slovenia
                [7 ]Department of Thoracic Surgery, St James's University Hospital, Leeds, UK
                Author notes
                Corresponding author: Alessandro Brunelli ( brunellialex@ 123456gmail.com )
                Author information
                https://orcid.org/0000-0002-7787-991X
                https://orcid.org/0000-0002-9349-7022
                https://orcid.org/0000-0001-7041-6368
                https://orcid.org/0000-0002-3318-0146
                https://orcid.org/0000-0003-3891-6180
                https://orcid.org/0000-0002-9019-806X
                https://orcid.org/0000-0002-6505-1656
                Article
                ERR-0195-2023
                10.1183/16000617.0195-2023
                10951859
                38508666
                be6b202c-c320-4c06-ac8f-f45a6bd9a485
                Copyright ©The authors 2024

                This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ 123456ersnet.org

                History
                : 09 October 2023
                : 11 January 2024
                Categories
                Reviews
                6

                Comments

                Comment on this article